{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:54:08Z","timestamp":1772045648732,"version":"3.50.1"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA237619"],"award-info":[{"award-number":["CA237619"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40266-025-01214-4","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T03:18:47Z","timestamp":1747538327000},"page":"599-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Managing Rheumatoid Arthritis in Older Adults with Cancer"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-8393","authenticated-orcid":false,"given":"Maria A.","family":"Lopez-Olivo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliza R. Karpes","family":"Matusevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean H.","family":"Tayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"10055","key":"1214_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"7","key":"1214_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1214_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/art.10897","volume":"48","author":"EK Rasch","year":"2003","unstructured":"Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 2003;48(4):917\u201326.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1214_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-Zugich","year":"2018","unstructured":"Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10\u20139.","journal-title":"Nat Immunol"},{"issue":"6","key":"1214_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun Rev. 2020;19(6): 102528.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1214_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1214_CR7","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/ar2404","volume":"10","author":"AL Smitten","year":"2008","unstructured":"Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.","journal-title":"Arthritis Res Ther"},{"key":"1214_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100768","volume":"35","author":"M Beydon","year":"2023","unstructured":"Beydon M, Pinto S, De Rycke Y, Fautrel B, Mariette X, Seror R, Tubach F. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg Health Eur. 2023;35: 100768.","journal-title":"Lancet Reg Health Eur."},{"key":"1214_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6472-9","author":"H Fowler","year":"2020","unstructured":"Fowler H, Belot A, Ellis L, Maringe C, Luque-Fernandez MA, Njagi EN, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer. 2020. https:\/\/doi.org\/10.1186\/s12885-019-6472-9.","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"1214_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/0284186X.2015.1114670","volume":"55","author":"JK Pedersen","year":"2016","unstructured":"Pedersen JK, Engholm G, Skytthe A, Christensen K, Academy of Geriatric Cancer R. Cancer and aging: epidemiology and methodological challenges. Acta Oncol. 2016;55(Suppl 1):7\u201312.","journal-title":"Acta Oncol"},{"issue":"6","key":"1214_CR11","first-page":"1001","volume":"20","author":"A Parikh-Patel","year":"2009","unstructured":"Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Cause Control. 2009;20(6):1001\u201310.","journal-title":"Cancer Cause Control."},{"issue":"10","key":"1214_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","volume":"9","author":"AM Boots","year":"2013","unstructured":"Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(10):604\u201313.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1214_CR13","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1038\/s41467-023-43091-8","volume":"14","author":"EA James","year":"2023","unstructured":"James EA, Holers VM, Iyer R, Prideaux EB, Rao NL, Rims C, et al. Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis. Nat Commun. 2023;14(1):7637.","journal-title":"Nat Commun"},{"issue":"10","key":"1214_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/cells7100161","volume":"7","author":"HY Yap","year":"2018","unstructured":"Yap HY, Tee SZ, Wong MM, Chow SK, Peh SC, Teow SY. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells. 2018;7(10):161.","journal-title":"Cells"},{"issue":"1","key":"1214_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"4","key":"1214_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1054\/bjoc.2001.1943","volume":"85","author":"KJ O'Byrne","year":"2001","unstructured":"O\u2019Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85(4):473\u201383.","journal-title":"Br J Cancer"},{"issue":"9","key":"1214_CR17","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1136\/annrheumdis-2013-204912","volume":"74","author":"AJ Ytterberg","year":"2015","unstructured":"Ytterberg AJ, Joshua V, Reynisdottir G, Tarasova NK, Rutishauser D, Ossipova E, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. 2015;74(9):1772\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1214_CR18","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/ard.2007.075192","volume":"67","author":"D Makrygiannakis","year":"2008","unstructured":"Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1214_CR19","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2015-208216","volume":"75","author":"G Reynisdottir","year":"2016","unstructured":"Reynisdottir G, Olsen H, Joshua V, Engstrom M, Forsslund H, Karimi R, et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann Rheum Dis. 2016;75(9):1722\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1214_CR20","doi-asserted-by":"publisher","first-page":"4609486","DOI":"10.1155\/2016\/4609486","volume":"2016","author":"S Raheel","year":"2016","unstructured":"Raheel S, Crowson CS, Wright K, Matteson EL. Risk of malignant neoplasm in patients with incident rheumatoid arthritis 1980\u20132007 in relation to a comparator cohort: a population-based study. Int J Rheumatol. 2016;2016:4609486.","journal-title":"Int J Rheumatol"},{"issue":"1","key":"1214_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/annonc\/mdu470","volume":"26","author":"A Wang","year":"2015","unstructured":"Wang A, Kubo J, Luo J, Desai M, Hedlin H, Henderson M, et al. Active and passive smoking in relation to lung cancer incidence in the Women\u2019s Health Initiative Observational Study prospective cohort. Ann Oncol. 2015;26(1):221\u201330.","journal-title":"Ann Oncol"},{"issue":"6","key":"1214_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/carcin\/bgab018","volume":"42","author":"G Jia","year":"2021","unstructured":"Jia G, Wen W, Massion PP, Shu XO, Zheng W. Incorporating both genetic and tobacco smoking data to identify high-risk smokers for lung cancer screening. Carcinogenesis. 2021;42(6):874\u20139.","journal-title":"Carcinogenesis"},{"issue":"3","key":"1214_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/ard.60.3.223","volume":"60","author":"D Hutchinson","year":"2001","unstructured":"Hutchinson D, Shepstone L, Moots R, Lear JT, Lynch MP. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis. 2001;60(3):223\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1214_CR24","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2383","volume":"10","author":"A Naranjo","year":"2008","unstructured":"Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):R30.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1214_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000506","volume":"3","author":"RM Joseph","year":"2017","unstructured":"Joseph RM, Movahedi M, Dixon WG, Symmons DP. Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink. RMD Open. 2017;3(2): e000506.","journal-title":"RMD Open"},{"issue":"4","key":"1214_CR26","volume":"12","author":"B Bhandari","year":"2020","unstructured":"Bhandari B, Basyal B, Sarao MS, Nookala V, Thein Y. Prevalence of cancer in rheumatoid arthritis: epidemiological study based on the National Health and Nutrition Examination Survey (NHANES). Cureus. 2020;12(4): e7870.","journal-title":"Cureus."},{"issue":"6","key":"1214_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.trecan.2020.12.010","volume":"7","author":"G Panigrahi","year":"2021","unstructured":"Panigrahi G, Ambs S. How comorbidities shape cancer biology and survival. Trends Cancer. 2021;7(6):488\u201395.","journal-title":"Trends Cancer."},{"key":"1214_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-016-1038-3","volume":"17","author":"M van Onna","year":"2016","unstructured":"van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskel Dis. 2016;17:1\u20139.","journal-title":"BMC Musculoskel Dis."},{"issue":"6","key":"1214_CR29","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740\u201351.","journal-title":"Arthritis Rheum"},{"key":"1214_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1874312901711010088","volume":"11","author":"D Murphy","year":"2017","unstructured":"Murphy D, Hutchinson D. Is male rheumatoid arthritis an occupational disease? A review. Open Rheumatol J. 2017;11:88\u2013105.","journal-title":"Open Rheumatol J."},{"issue":"2","key":"1214_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37530","volume":"4","author":"N Li","year":"2021","unstructured":"Li N, Zhai Z, Zheng Y, Lin S, Deng Y, Xiang G, et al. Association of 13 occupational carcinogens in patients with cancer, individually and collectively, 1990\u20132017. JAMA Netw Open. 2021;4(2): e2037530.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1214_CR32","doi-asserted-by":"publisher","first-page":"e003176","DOI":"10.1136\/rmdopen-2023-003176","volume":"9","author":"M Cutolo","year":"2023","unstructured":"Cutolo M, Gotelli E. Complex role of oestrogens in the risk and severity of rheumatoid arthritis in menopause. RMD Open. 2023;9(2):e003176.","journal-title":"RMD Open"},{"issue":"4","key":"1214_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers14040909","volume":"14","author":"AT Harding","year":"2022","unstructured":"Harding AT, Heaton NS. The impact of estrogens and their receptors on immunity and inflammation during infection. Cancers. 2022;14(4):909.","journal-title":"Cancers"},{"issue":"3","key":"1214_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692\u2013701.","journal-title":"Arthritis Rheum"},{"issue":"7152","key":"1214_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","volume":"317","author":"E Baecklund","year":"1998","unstructured":"Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317(7152):180\u20131.","journal-title":"BMJ"},{"key":"1214_CR36","doi-asserted-by":"publisher","first-page":"1050876","DOI":"10.3389\/fimmu.2022.1050876","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lin J, You Z, Tu H, He P, Li J, et al. Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: will immunosuppressants work? Front Immunol. 2022;13:1050876.","journal-title":"Front Immunol"},{"issue":"10","key":"1214_CR37","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/art.1780401016","volume":"40","author":"JM Kremer","year":"1997","unstructured":"Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40(10):1829\u201337.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1214_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14740338.4.4.723","volume":"4","author":"O Lateef","year":"2005","unstructured":"Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723\u201330.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1214_CR39","first-page":"153","volume":"20","author":"BD Jakubovic","year":"2013","unstructured":"Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Can Respir J. 2013;20(3):153\u20135.","journal-title":"Can Respir J"},{"issue":"3","key":"1214_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5414\/CP203604","volume":"58","author":"R Inose","year":"2020","unstructured":"Inose R, Hashimoto N, Hosomi K, Yokoyama S, Takada M. Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2020;58(3):131\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"1214_CR41","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1136\/rmdopen-2020-001363","volume":"6","author":"K Chatzidionysiou","year":"2020","unstructured":"Chatzidionysiou K, Delcoigne B, Frisell T, Hetland ML, Glintborg B, Dreyer L, et al. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open. 2020;6(2):e001363.","journal-title":"RMD Open"},{"issue":"3","key":"1214_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348.","journal-title":"Int Immunol"},{"issue":"9","key":"1214_CR43","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/2012.jama.10857","volume":"308","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898\u2013908.","journal-title":"JAMA"},{"key":"1214_CR44","first-page":"506","volume":"74","author":"J Molina","year":"2022","unstructured":"Molina J, Sanchez-Alonso F, Bohorquez C, Diaz-Torne C, Perez-Garcia C, Blanco-Madrigal JM, et al. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancy: results from the BIOBADASER register. Arthritis Rheumatol. 2022;74:506\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1214_CR45","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1214_CR46","doi-asserted-by":"publisher","first-page":"e15070","DOI":"10.1111\/1756-185X.15070","volume":"27","author":"HM Lee","year":"2024","unstructured":"Lee HM, Chi HT, Wei JCC. Hunting uncertainties: JAK inhibitors and cancer risk. Int J Rheum Dis. 2024;27(2):e15070.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"1214_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/acr.23865","volume":"72","author":"MA Lopez-Olivo","year":"2020","unstructured":"Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, et al. Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res (Hoboken). 2020;72(3):309\u201318.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"2","key":"1214_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40744-017-0064-4","volume":"4","author":"KM Wilton","year":"2017","unstructured":"Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333\u201347.","journal-title":"Rheumatol Ther."},{"issue":"6","key":"1214_CR49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.semarthrit.2007.08.006","volume":"37","author":"L Abasolo","year":"2008","unstructured":"Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L, Group ES. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum. 2008;37(6):388\u201397.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1214_CR50","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/annrheumdis-2014-207155","volume":"75","author":"JF Simard","year":"2016","unstructured":"Simard JF, Ekberg S, Johansson AL, Askling J. What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer? Ann Rheum Dis. 2016;75(5):862\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1214_CR51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/rheumatology\/ker143","volume":"50","author":"J Ji","year":"2011","unstructured":"Ji J, Liu X, Sundquist K, Sundquist J. Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology (Oxford). 2011;50(8):1513\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1214_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/acr.22997","volume":"69","author":"P Nayak","year":"2017","unstructured":"Nayak P, Luo R, Elting L, Zhao H, Suarez-Almazor ME. Impact of rheumatoid arthritis on the mortality of elderly patients who develop cancer: a population-based study. Arthritis Care Res (Hoboken). 2017;69(1):75\u201383.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1214_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/453012","volume":"2014","author":"G Tian","year":"2014","unstructured":"Tian G, Liang JN, Wang ZY, Zhou D. Breast cancer risk in rheumatoid arthritis: an update meta-analysis. Biomed Res Int. 2014;2014: 453012.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1214_CR54","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO.2005.04.6227","volume":"24","author":"TR Mikuls","year":"2006","unstructured":"Mikuls TR, Endo JO, Puumala SE, Aoun PA, Black NA, O\u2019Dell JR, et al. Prospective study of survival outcomes in Non-Hodgkin\u2019s lymphoma patients with rheumatoid arthritis. J Clin Oncol. 2006;24(10):1597\u2013602.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1214_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ejh.12116","volume":"91","author":"A Ichikawa","year":"2013","unstructured":"Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein\u2013Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20\u20138.","journal-title":"Eur J Haematol"},{"issue":"6","key":"1214_CR56","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.11144","volume":"48","author":"E Baecklund","year":"2003","unstructured":"Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 2003;48(6):1543\u201350.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1214_CR57","first-page":"322","volume":"34","author":"Y Hoshida","year":"2007","unstructured":"Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322\u201331.","journal-title":"J Rheumatol"},{"issue":"8","key":"1214_CR58","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/rheumatology\/ker143","volume":"50","author":"JG Ji","year":"2011","unstructured":"Ji JG, Liu XD, Sundquist K, Sundquist J. Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology. 2011;50(8):1513\u20138.","journal-title":"Rheumatology"},{"issue":"12","key":"1214_CR59","doi-asserted-by":"publisher","first-page":"13086","DOI":"10.1002\/cam4.5989","volume":"12","author":"D Dedousis","year":"2023","unstructured":"Dedousis D, Zhang AL, Vassiliou AN, Cao S, Yammani D, Kyasaram RK, et al. Survival in elderly patients with breast cancer with and without autoimmune disease. Cancer Med. 2023;12(12):13086\u201399.","journal-title":"Cancer Med"},{"key":"1214_CR60","unstructured":"Institute for Health Metrics and Evaluation. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study. 2019. https:\/\/vizhub.healthdata.org\/gbd-results\/. Accessed 20 Nov 2024."},{"issue":"2","key":"1214_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0889-857X(05)70201-5","volume":"27","author":"SE Gabriel","year":"2001","unstructured":"Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):269\u201381.","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"1214_CR62","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/ard.2005.044784","volume":"65","author":"J Franklin","year":"2006","unstructured":"Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis. 2006;65(5):617\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1214_CR63","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0049-0172(97)80023-6","volume":"26","author":"L Georgescu","year":"1997","unstructured":"Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26(6):794\u2013804.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"1214_CR64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/cas.13249","volume":"108","author":"Y Gion","year":"2017","unstructured":"Gion Y, Iwaki N, Takata K, Takeuchi M, Nishida K, Orita Y, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108(6):1271\u201380.","journal-title":"Cancer Sci"},{"issue":"3","key":"1214_CR65","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3109\/10428194.2014.928936","volume":"56","author":"S Maegawa","year":"2015","unstructured":"Maegawa S, Kuroda J, Kobayashi T, Fuchida S, Kawata E, Kamitsuji Y, et al. Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(3):785\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1214_CR66","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/10428194.2017.1369073","volume":"59","author":"M Tokuhira","year":"2018","unstructured":"Tokuhira M, Saito S, Okuyama A, Suzuki K, Higashi M, Momose S, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018;59(5):1143\u201352.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1214_CR67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3109\/10428194.2011.625101","volume":"53","author":"M Tokuhira","year":"2012","unstructured":"Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012;53(4):616\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"1214_CR68","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/jnci\/djh313","volume":"96","author":"WH Feng","year":"2004","unstructured":"Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein\u2013Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22):1691\u2013702.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1214_CR69","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1214_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1214_CR71","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","volume":"2","author":"SA Khan","year":"2016","unstructured":"Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2(11):1507\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1214_CR72","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1186\/s12885-021-09001-1","volume":"21","author":"AN Holmes","year":"2021","unstructured":"Holmes AN, Swede H, Feer WM, Pike DC, Wang X, Hegde UP. Association of advanced age and cancer history with autoimmune disease in melanoma patients: a cross-sectional study. BMC Cancer. 2021;21(1):1300.","journal-title":"BMC Cancer"},{"issue":"10","key":"1214_CR73","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1093\/rheumatology\/kead075","volume":"62","author":"H Miyata","year":"2023","unstructured":"Miyata H, Sonomoto K, Fukuyo S, Nakayamada S, Nakano K, Iwata S, et al. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. Rheumatology. 2023;62(10):3339\u201349.","journal-title":"Rheumatology"},{"issue":"6","key":"1214_CR74","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/rheumatology\/kead478","volume":"63","author":"M Lorenzon","year":"2024","unstructured":"Lorenzon M, Zabotti A, Cereser L. Cancer screening before treatments in rheumatoid arthritis: lights and shadows. Rheumatology. 2024;63(6):1475\u20136.","journal-title":"Rheumatology"},{"key":"1214_CR75","unstructured":"US Preventive Services Task Force. Published recommendations. 2024. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/topic_search_results?topic_status=P. Accessed 20 Nov 2024."},{"issue":"3","key":"1214_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.rdc.2020.05.003","volume":"46","author":"X Pundole","year":"2020","unstructured":"Pundole X, Suarez-Almazor ME. Cancer and rheumatoid arthritis. Rheum Dis Clin N Am. 2020;46(3):445\u201362.","journal-title":"Rheum Dis Clin N Am"},{"issue":"11","key":"1214_CR77","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s10067-024-07135-8","volume":"43","author":"ME Suarez-Almazor","year":"2024","unstructured":"Suarez-Almazor ME, Ruiz JI, Lei X, Wu CF, Zhao H, Rajan SS, Giordano SH. Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. Clin Rheumatol. 2024;43(11):3301\u201312.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1214_CR78","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s10067-022-06478-4","volume":"42","author":"Y Ingrasciotta","year":"2023","unstructured":"Ingrasciotta Y, Jin Y, Foti SS, Landon JE, Tari M, Mattace-Raso F, et al. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study. Clin Rheumatol. 2023;42(4):1047\u201359.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1214_CR79","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10067-019-04874-x","volume":"39","author":"X Pundole","year":"2020","unstructured":"Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Hong LC, et al. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. Clin Rheumatol. 2020;39(3):787\u201394.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"1214_CR80","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s10067-020-05318-7","volume":"39","author":"X Pundole","year":"2020","unstructured":"Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Leung CH, et al. Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clin Rheumatol. 2020;39(10):2943\u201350.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1214_CR81","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/acr.23781","volume":"71","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, et al. Long-Term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry. Arthritis Care Res (Hoboken). 2018;71(8):993\u20131003.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"1214_CR82","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3899\/jrheum.140853","volume":"42","author":"KJ Aaltonen","year":"2015","unstructured":"Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015;42(3):372\u20138.","journal-title":"J Rheumatol"},{"issue":"10","key":"1214_CR83","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s10067-015-3026-7","volume":"34","author":"N Berghen","year":"2015","unstructured":"Berghen N, Teuwen LA, Westhovens R, Verschueren P. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol. 2015;34(10):1687\u201395.","journal-title":"Clin Rheumatol"},{"key":"1214_CR84","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/annrheumdis-2015-eular.3822","volume":"74","author":"JE Gottenberg","year":"2015","unstructured":"Gottenberg JE, Morel J, Ravaud P, Bardin T, Cacoub P, Cantagrel A, et al. Incidence of cancers in patients with rheumatoid arthritis and a history of cancer treated with rituximab or abatacept. Ann Rheum Dis. 2015;74:478\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1214_CR85","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/jdv.12675","volume":"29","author":"PP van Lumig","year":"2015","unstructured":"van Lumig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015;29(4):752\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1214_CR86","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jbspin.2010.11.012","volume":"78","author":"S Slimani","year":"2011","unstructured":"Slimani S, Lukas C, Combe B, Morel J. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine. 2011;78(5):484\u20137.","journal-title":"Joint Bone Spine"},{"key":"1214_CR87","unstructured":"Yamasaki M. The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with\/without Prior Cancers [abstract]. Arthritis\nRheumatol. 2018;70(suppl 9). https:\/\/acrabstracts.org\/abstract\/the-risk-of-solid-cancers-in-patients-with-rheumatoid-arthritis-exposed-to-biologicdmards-with-without-prior-cancers\/. Accessed 16 May 2025."},{"issue":"5","key":"1214_CR88","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/rheumatology\/kez475","volume":"59","author":"W Xie","year":"2020","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Gao D, Ji L, et al. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford). 2020;59(5):930\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1214_CR89","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/acr.24784","volume":"75","author":"A Wetzman","year":"2023","unstructured":"Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B, et al. Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. Arthritis Care Res (Hoboken). 2023;75(2):260\u201371.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"1214_CR90","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/annrheumdis-2017-212086","volume":"77","author":"L Dreyer","year":"2018","unstructured":"Dreyer L, Cordtz RL, Hansen IMJ, Kristensen LE, Hetland ML, Mellemkjaer L. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis. 2018;77(4):510\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1214_CR91","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1699-258X(06)73026-1","volume":"2","author":"R Burgos-Vargas","year":"2006","unstructured":"Burgos-Vargas R. Guidelines and recommendations of the Mexican College of Rheumatology on the use of biological agents in patients with rheumatic disease [Spanish]. Reumatol Clin. 2006;2(2):78\u201389.","journal-title":"Reumatol Clin"},{"key":"1214_CR92","first-page":"112","volume":"42","author":"C Duarte","year":"2017","unstructured":"Duarte C, Sousa-Neves J, Agueda A, Ribeiro P, Daniel A, Eugenio G, et al. Portuguese recommendations for the use of biological therapies in patients with rheumatoid arthritis\u20142016 update. Acta Reumatol Port. 2017;42:112\u201326.","journal-title":"Acta Reumatol Port"},{"issue":"Suppl 1","key":"1214_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1297-319X(11)70001-X","volume":"78","author":"T Pham","year":"2011","unstructured":"Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, et al. TNF alpha antagonist therapy and safety monitoring. Jt Bone Spine Rev Rhum. 2011;78(Suppl 1):15\u2013185.","journal-title":"Jt Bone Spine Rev Rhum"},{"issue":"5","key":"1214_CR94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.reuma.2015.05.001","volume":"11","author":"R Sanmarti","year":"2015","unstructured":"Sanmarti R, Garcia-Rodriguez S, Alvaro-Gracia JM, Andreu JL, Balsa A, Caliz R, et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol Clin. 2015;11(5):279\u201394.","journal-title":"Reumatol Clin"},{"issue":"Suppl 1","key":"1214_CR95","first-page":"S1","volume":"75","author":"T Pham","year":"2008","unstructured":"Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Jt Bone Spine Rev Rhum. 2008;75(Suppl 1):S1-99.","journal-title":"Jt Bone Spine Rev Rhum"},{"issue":"2","key":"1214_CR96","first-page":"158","volume":"53","author":"LM da Mota","year":"2013","unstructured":"da Mota LM, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB, et al. Guidelines for the drug treatment of rheumatoid arthritis. [Erratum appears in Rev Bras Reumatol. 2013 May-Jun;53(3):319 Note: Giorgio, Rina Dalva Neubarth [corrected to Giorgi, Rina Dalva Neubarth]]. Review. 2013;53(2):158\u201383.","journal-title":"Review"},{"issue":"2","key":"1214_CR97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00393-013-1238-2","volume":"73","author":"A Rubbert-Roth","year":"2014","unstructured":"Rubbert-Roth A, Burmester GR, Dorner T, Gause A, Kommission Pharmakotherapie Der D. Recommendations for use of rituximab in patients with rheumatoid arthritis. Z Rheumatol. 2014;73(2):165\u201374.","journal-title":"Z Rheumatol"},{"issue":"7","key":"1214_CR98","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015;18(7):685\u2013713.","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 1","key":"1214_CR99","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1297-319X(10)70001-4","volume":"77","author":"T Pham","year":"2010","unstructured":"Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, et al. Tocilizumab: therapy and safety management. Jt Bone Spine Rev Rhum. 2010;77(Suppl 1):S3-100.","journal-title":"Jt Bone Spine Rev Rhum"},{"issue":"1","key":"1214_CR100","first-page":"7","volume":"5","author":"CC Mok","year":"2005","unstructured":"Mok CC. Consensus statements on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong. Hong Kong Bull Rheum Dis. 2005;5(1):7.","journal-title":"Hong Kong Bull Rheum Dis"},{"issue":"4","key":"1214_CR101","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/s10165-009-0197-6","volume":"19","author":"R Koike","year":"2009","unstructured":"Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19(4):351\u20137.","journal-title":"Mod Rheumatol"},{"key":"1214_CR102","unstructured":"Centro Nacional de Excelencia Tecnol\u00f3gica en Salud. Diagn\u00f3stico y Tratamiento de Artritis Reumatoide del Adulto Mexico: CENETEC; 2010. https:\/\/www.cenetec-difusion.com\/CMGPC\/IMSS-195-10\/ER.pdf. Accessed 16 May 2025."},{"issue":"1","key":"1214_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1\u201325.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1214_CR104","unstructured":"National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis (Structured abstract). Health Technology Assessment Database [Internet]. 2002; (2):[22 p.]. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clhta\/articles\/HTA-32002000354\/frame.html."},{"issue":"6","key":"1214_CR105","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/s10165-007-0626-3","volume":"17","author":"R Koike","year":"2007","unstructured":"Koike R, Takeuchi T, Eguchi K, Miyasaka N, Japan College of R. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451\u20138.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1214_CR106","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1214_CR107","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3899\/jrheum.120165","volume":"39","author":"C Bombardier","year":"2012","unstructured":"Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol. 2012;39(8):1583\u2013602.","journal-title":"J Rheumatol"},{"issue":"1","key":"1214_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/14397595.2021.1899570","volume":"32","author":"H Takada","year":"2022","unstructured":"Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, et al. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study. Mod Rheumatol. 2022;32(1):32\u201340.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1214_CR109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/14397595.2020.1869370","volume":"32","author":"S Honda","year":"2022","unstructured":"Honda S, Sakai R, Inoue E, Majima M, Konda N, Takada H, et al. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study. Mod Rheumatol. 2022;32(1):16\u201323.","journal-title":"Mod Rheumatol"},{"key":"1214_CR110","doi-asserted-by":"publisher","first-page":"152301","DOI":"10.1016\/j.semarthrit.2023.152301","volume":"63","author":"M Mizushima","year":"2023","unstructured":"Mizushima M, Sugihara T, Matsui T, Urata Y, Tohma S, Kawahata K. Comparison between rheumatoid arthritis with malignant lymphoma and other malignancies: analysis of a National Database of Rheumatic Disease in Japan. Semin Arthritis Rheum. 2023;63:152301.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1214_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/road098","volume":"34","author":"H Kameda","year":"2023","unstructured":"Kameda H, Yamaoka K, Yamanishi Y, Tada M, Koike R, Nakajima A, et al. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication. Mod Rheumatol. 2023;34(1):1\u201310.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1214_CR112","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14397595.2020.1847775","volume":"32","author":"K Nakano","year":"2022","unstructured":"Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, et al. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Mod Rheumatol. 2022;32(1):41\u20139.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"1214_CR113","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/acr2.11552","volume":"5","author":"N Singh","year":"2023","unstructured":"Singh N, Grivas P, Makris UE, Suarez-Almazor ME, O\u2019Hare AM, Barton JL. Use of disease-modifying antirheumatic drugs in rheumatoid arthritis: supporting shared decision-making between patients with cancer and clinicians. ACR Open Rheumatol. 2023;5(6):305\u20137.","journal-title":"ACR Open Rheumatol."},{"issue":"2","key":"1214_CR114","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1017\/S071498080000146X","volume":"21","author":"M Pr\u00e9ville","year":"2002","unstructured":"Pr\u00e9ville M, H\u00e9bert R, Bravo G, Boyer R. Predisposing and facilitating factors of severe psychological distress among frail elderly adults. Can J Aging. 2002;21(2):195\u2013204.","journal-title":"Can J Aging"},{"issue":"1","key":"1214_CR115","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.archger.2004.12.004","volume":"41","author":"M Couture","year":"2005","unstructured":"Couture M, Lariviere N, Lefrancois R. Psychological distress in older adults with low functional independence: a multidimensional perspective. Arch Gerontol Geriatr. 2005;41(1):101\u201311.","journal-title":"Arch Gerontol Geriatr"},{"issue":"26","key":"1214_CR116","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1200\/JCO.2008.19.9463","volume":"27","author":"A Hurria","year":"2009","unstructured":"Hurria A, Li D, Hansen K, Patil S, Gupta R, Nelson C, et al. Distress in older patients with cancer. J Clin Oncol. 2009;27(26):4346\u201351.","journal-title":"J Clin Oncol"},{"key":"1214_CR117","unstructured":"Institute of Medicine (US) Committee on Psychosocial Services to Cancer Patients\/Families in a Community Setting, Adler NE, Page AEK, editors. The Psychosocial Needs of Cancer Patients. In Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs Washington (DC): National Academies Press (US). 2008. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK4011\/. Accessed 04 Dec 2024."},{"issue":"2","key":"1214_CR118","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/13607863.2019.1693972","volume":"25","author":"B Martins-Klein","year":"2021","unstructured":"Martins-Klein B, Bamonti PM, Owsiany M, Naik A, Moye J. Age differences in cancer-related stress, spontaneous emotion regulation, and emotional distress. Aging Ment Health. 2021;25(2):250\u20139.","journal-title":"Aging Ment Health"},{"issue":"1","key":"1214_CR119","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12904-023-01202-8","volume":"22","author":"CA Paley","year":"2023","unstructured":"Paley CA, Boland JW, Santarelli M, Murtagh FEM, Ziegler L, Chapman EJ. Non-pharmacological interventions to manage psychological distress in patients living with cancer: a systematic review. BMC Palliat Care. 2023;22(1):88.","journal-title":"BMC Palliat Care"},{"issue":"1","key":"1214_CR120","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","volume":"82","author":"JM Gwinnutt","year":"2023","unstructured":"Gwinnutt JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, Boonen A, Cavalli G, et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):48\u201356.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1214_CR121","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/nu16060800","volume":"16","author":"P Marino","year":"2024","unstructured":"Marino P, Mininni M, Deiana G, Marino G, Divella R, Bochicchio I, et al. Healthy lifestyle and cancer risk: modifiable risk factors to prevent cancer. Nutrients. 2024;16(6):800.","journal-title":"Nutrients"},{"key":"1214_CR122","unstructured":"Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. [Updated 2023 Feb 27]. In: StatPearls [Internet]. . Treasure Island (FL): StatPearls Publishing. 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564367\/. Accessed 5 Dec 2024."},{"issue":"14","key":"1214_CR123","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(14):1699\u2013721.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1214_CR124","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/vaccines11050943","volume":"11","author":"FK Yilmaz","year":"2023","unstructured":"Yilmaz FK, Cakir M, Ikiisik H, Maral I. The effect of pneumococcal, influenza, and COVID-19 vaccinations on COVID-19 hospitalization and progression in people over 65 years old living in nursing homes. Vaccines (Basel). 2023;11(5):943.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1214_CR125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39\u201352.","journal-title":"Ann Rheum Dis"},{"key":"1214_CR126","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.21037\/tlcr.2019.04.01","volume":"8","author":"J Jassem","year":"2019","unstructured":"Jassem J. Tobacco smoking after diagnosis of cancer: clinical aspects. Transl Lung Cancer R. 2019;8:S50\u20138.","journal-title":"Transl Lung Cancer R."},{"issue":"4","key":"1214_CR127","first-page":"263","volume":"25","author":"V Bagnardi","year":"2001","unstructured":"Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health. 2001;25(4):263\u201370.","journal-title":"Alcohol Res Health"},{"issue":"3","key":"1214_CR128","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","volume":"79","author":"TJ Braaten","year":"2020","unstructured":"Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1214_CR129","doi-asserted-by":"publisher","first-page":"114148","DOI":"10.1016\/j.ejca.2024.114148","volume":"207","author":"MA Lopez-Olivo","year":"2024","unstructured":"Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, et al. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease. Eur J Cancer. 2024;207:114148.","journal-title":"Eur J Cancer"},{"issue":"Suppl 3","key":"1214_CR130","first-page":"21","volume":"10","author":"S Adkins","year":"2019","unstructured":"Adkins S. CAR T-cell therapy: adverse events and management. J Adv Pract Oncol. 2019;10(Suppl 3):21\u20138.","journal-title":"J Adv Pract Oncol"},{"issue":"16","key":"1214_CR131","doi-asserted-by":"publisher","first-page":"e24090","DOI":"10.1200\/JCO.2023.41.16_suppl.e24090","volume":"41","author":"MA Lopez-Olivo","year":"2023","unstructured":"Lopez-Olivo MA, Sharma G, Qureshi S, Hicklen RS, Tayar JH, Suarez-Almazor ME. Adverse events with the use of radiotherapy in patients with inflammatory arthritides and cancer: a systematic review and meta-analysis. J Clin Oncol. 2023;41(16):e24090.","journal-title":"J Clin Oncol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01214-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01214-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01214-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:54:07Z","timestamp":1757170447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01214-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":131,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01214-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Lopez-Olivo\u2019s work was supported by the National Cancer Institute (project number CA237619) and the Rheumatology Research Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Lopez-Olivo is an Editorial Board member of Drugs & Aging. Dr. Lopez-Olivo was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The remaining authors have no competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article is a narrative literature review and does not involve any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval (appropriate approvals or waivers)"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable. This review is based on previously published literature retrieved from MEDLINE and treatment recommendations extracted from a prior review of clinical practice guidelines by the authors, Lopez-Olivo et al. (Arthritis Care Res 2019;72:309\u2013318).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"Lopez-Olivo MA: conceptualization, writing\u2014original draft, review and editing. Karpes Matusevich AR: investigation, validation, writing\u2014review and editing. Tayar JH: writing\u2014review and editing. Lu H: writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}